British American Tobacco: BAT Conducts First Real-Life Study Assessing Impact of Vuse on Indicators of Multiple Smoking-Related Diseases

  • The results will provide a one-of-a-kind data set – adding to the substantial amounts of scientific evidence generated on Vuse, the world’s number one vaping brand.I
  • Unique cross-sectional approach will provide insight into differences in potential harm indicators between Vuse users and smokers
  • Demonstrates BAT’s focus on science and innovation to deliver A Better Tomorrow™ and reduce the health impact of its business

BAT conducted a first-of-its-kind study on Vuse, designed to assess and provide insight into the true health impact of vaping. Study compares biomarker measurements of Vuseii consumers who have used the product for more than six months with the results of smokers, former smokers and never smokers. Details of the protocol explaining the innovative design of the latest study have been published in the Health and Environment Research Journaliii.

The cross-sectional study design uses a unique set of data readouts to measure exposure to certain toxicants and indicators of potential harm from several smoking-related diseases in people who use Vuse exclusively.

The selected biomarkers are important indicators that can be used to demonstrate:

  • Biomarkers of exposure: A person’s exposure to certain toxins or chemicalsiv

  • Biomarkers of potential damage: indicators of potential damage related to several smoking-related diseases, such as respiratory or cardiovascular diseasesiii

It is hoped that the results, which are currently being analyzed and will be published later this year, will provide further evidence that Vuse use may reduce the relative risk of certain diseases in adult consumers compared to smoking. It is expected that once available, the results will add to the growing body of evidence on Vuse’s potential as a reduced risk product*.

Dr Sharon Goodall, Head of BAT’s Regulatory Science Group, said: “This groundbreaking study demonstrates our commitment to researching the risk reduction potential of our new category products. What makes it particularly relevant and exciting is that the results generated will come from people who have been using Vuse as they normally would for more than six months before testing. The results will provide important new information and show us the differences between Vuse users, current smokers, and former smokers on a range of important biomarkers thought to predict disease development. We are eager to share the data once available.

About the study
Study participants were Vuseii users who had exclusively used the product for more than six months. Smoking or vaping habits and overall consumption were not controlled for in people entering the study, as the aim was to assess the impact when people using the products did so ” normal” rather than in a controlled manner. Four different groups were registered.

These included:

  1. Current smokers who had smoked for at least one year prior to testing

  2. See vapers (ePod and ePen) for at least six months

  3. Former smokers who have quit for at least six months

  4. Non-smokers were included to serve as a control group

The participants were UK-based, aged 19 to 55, and in generally good health.

Unlike longitudinal studies where participants attend multiple clinic visits over an extended period of time, participants in this study completed a single clinic visit where samples of blood, urine, and other measurements were taken. collected. These samples were then tested for “biomarkers of exposure” (to certain toxicants in cigarette smoke) and “biomarkers of potential harm”. Differences between groups were assessed, rather than changes from baseline.

Additionally, to ensure compliance, the Vuse and ex-smokers groups were tested for the biomarker, CEVal, which indicates whether they had recently smoked cigarettes.

The results of the completed study will be published in due course.

*Based on weight of evidence and assuming complete smoking cessation. These products are not without risk and are addictive.

† Our products as sold in the United States, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are regulated by the Food and Drug Administration (FDA) and no reduced risk claims will be made regarding these products without FDA clearance.

i Based on Vype/Vuse’s estimated value share from RRP in retail measured for Steam (i.e. total Steam category value in retail sales) at United States, Canada, France, United Kingdom and Germany. NTO system, calculated in June – July 2021.

ii Use ePod and/or ePen3. Both are closed steam systems

iii Nathan Gale, Linsey Ellen Haswell, Michael McEwan, David Azzopardi, Jesse Thissen, George Hardie. Biomarkers of exposure and potential harms among exclusive e-cigarette users and current, former, and never-smokers: a cross-sectional study protocol.

iv Journal of Health and Environmental Research. Flight. 8, no. 2, 2022, p. 116-127. doi: 10.11648/j.jher.20220802.17

v WHO Study Group on Tobacco Control. Report on the scientific basis of tobacco product regulation: Fifth report of a WHO study group. 2015.


media center
+44 (0) 20 7845 2888 (24 hours) | @BATplc

Investor Relations
Mike Nightingale: +44 (0)20 7845 1180
Victoria Buxton: +44 (0)20 7845 2012
William Houston: +44 (0)20 7845 1138
John Harney: +44 (0)20 7845 1263

Forward-looking statements

This release contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made using words or phrases such as ” believe”, “anticipate”, “could”, “may”, “should”, “should”, “intend”, “plan”, “potential”, “predict”, “will”, “would”, expects”, “estimates”, “project”, “positioned”, “strategy”, “outlook”, “target” and similar expressions. These include statements about our ambition towards customers, the revenue targets for new categories and our ESG objectives.

All of these forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. We believe that the expectations reflected in this release are reasonable, but may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A discussion of why actual results and developments may differ materially from the expectations disclosed or implied in the forward-looking statements can be found by referring to the information contained under the headings “Cautionary Statement” and “Principal Group Risks”. in the 2021 Annual Report. British American Tobacco plc (BAT) Report and Form 20-F.

Additional information regarding these and other factors may be found in BAT’s filings with the United States Securities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F and Current Reports. on Form 6-K, which can be obtained free of charge from the SEC website, and BAT’s annual reports, which can be obtained free of charge from BAT’s website

Past performance is not indicative of future performance and persons requiring advice should consult an independent financial adviser. Forward-looking statements reflect the knowledge and information available as of the date this release was prepared, and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.


Comments are closed.